Prudential Jennison Health Sciences

5 / 5 Stars
5 5 3 4 2
Zacks Investment Research
4 (Sell)
Standard & Poor's
3 / 5 Stars
B (Buy)

#11 in Health

U.S. News evaluated 33 Health Funds. Our list highlights the top-rated funds for long-term investors based on the ratings of leading fund industry researchers.

See all Prudential Investments funds

See full Health rankings

See more fund rankings


The fund has returned 38.31 percent over the past year, 28.09 percent over the past three years, 27.14 percent over the past five years, and 16.29 percent over the past decade.

Trailing Returns Updated 06.30.2014
Year to date 11.5%
1 Year 38.3%
3 Years (Annualized) 28.1%
5 Years (Annualized) 27.1%
10 Years (Annualized) 16.3%

See more PHLAX performance


The investment seeks long-term capital appreciation. The fund normally invests at least 80% of its investable assets in equity and equity-related securities of companies within the health sciences sector. It will invest in securities of issuers among a number of different countries throughout the world, one of which may be the United States. The portfolio managers use fundamental and quantitative analyses to select individual securities, and they may invest more than 5% of the fund's assets in any one issuer. The fund participates in the initial public offering (IPO) market. It is non-diversified.


Fees are Low compared to funds in the same category.
Prudential Jennison Health Sciences has an expense ratio of 1.18 percent.

See more PHLAX fees


Risk is Above Average compared to funds in the same category according to Morningstar.

See more PHLAX risk